Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California from Roche for $1.2 billion.   The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity to meet demand for commercial mammalian contract manufacturing from customers with existing commercial products, and molecules currently on the path to commerc...